Overview

A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

Status:
Completed
Trial end date:
2020-09-14
Target enrollment:
Participant gender:
Summary
Randomized, double-blind, placebo-controlled study on the effects of MIN-102 on Biochemical, Imaging, neurophysiological, and clinical markers in patients with Friedreich's Ataxia
Phase:
Phase 2
Details
Lead Sponsor:
Minoryx Therapeutics, S.L.